Novogene will validate Trovagene's proprietary urine collection and nucleic acid preservation device, NextCollect, and develop tests for the Chinese market.
The firm announced a 14 percent drop year-over-year in fourth quarter revenues and plans to reduce personnel and other costs to support development of a precision drug it has licensed.
The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.
The company believes that the reduction in staff and marketing costs for its testing services will reduce its annual pre-tax expenses by about $4 million.
The companies will co-develop kits, which Trovagene will distribute globally, to analyze ctDNA from blood or urine using next-generation sequencing platforms.
The increase was driven by higher demand for its diagnostic services related to its line of blood- and urine-based assays for the detection of cancer-associated genetic mutations.
The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
